Patents Represented by Attorney Bruce M. Eisen
  • Patent number: 6432919
    Abstract: Purified BMP-3 proteins and processes for producing them are disclosed. They may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
    Type: Grant
    Filed: March 4, 1991
    Date of Patent: August 13, 2002
    Assignee: Genetics Institute, Inc.
    Inventors: Elizabeth A. Wang, John M. Wozney, Vicki Rosen
  • Patent number: 5364839
    Abstract: Osteoinductive pharmaceutical formulations comprising antifibrinolytic agents such as epsilon amino acid caproic acid or other lysine analogues or serine protease inhibitors and cartilage and/or bone inductive proteins are disclosed. These formulations are useful in the treatment of cartilage and/or bone defects.
    Type: Grant
    Filed: June 18, 1990
    Date of Patent: November 15, 1994
    Assignee: Genetics Institute, Inc.
    Inventors: Tobin N. Gerhart, Elizabeth A. Wang, Mary J. Kriz
  • Patent number: 5322837
    Abstract: A method for purifying erythropoietin is described. The method comprises treating partially purifying erythropoietin by reverse phase high performance liquid chromatography to obtain homogeneous erythropoietin having a molecular weight of about 34,000 daltons on SDS PAGE and moving a single peak on reverse phase HPLC. The homogeneous erythropoietin protein preferably has a specific activity of at least 120,000 IU, more preferably at least 160,000 IU per absorbance unit at 280 nm.
    Type: Grant
    Filed: July 31, 1992
    Date of Patent: June 21, 1994
    Assignee: Genetics Institute, Inc.
    Inventors: Rodney M. Hewick, Jasbir S. Seenra
  • Patent number: 5322776
    Abstract: The invention provides novel DNA and peptide sequences encoding a family of phospholipase A.sub.2 enzymes, with specific activities of approximately 20 .mu.mol/min/mg in the mixed micelle assay. These enzymes are useful in methods for detecting the anti-inflammatory potential of various chemical agents. The invention also details novel methods for determining such potential using the novel sequences, methods for making the novel peptides, and methods for developing new anti-inflammatory drugs.
    Type: Grant
    Filed: January 13, 1993
    Date of Patent: June 21, 1994
    Assignee: Genetics Institute, Inc.
    Inventors: John L. Knopf, James Clark
  • Patent number: 5318898
    Abstract: An improved process for producing recombinant bone-inducing protein of the BMP-2 family as described. A suitable mammalian host cell transformed with a DNA encoding the protein is cultured in an appropriate culture medium to which is added about 10 to 1000 .mu.g/ml dextran sulfate. The presence of dextran sulfate in the medium results in an increased yield of recombinant bone-inducing protein.
    Type: Grant
    Filed: April 2, 1991
    Date of Patent: June 7, 1994
    Assignee: Genetics Institute, Inc.
    Inventor: David I. Israel
  • Patent number: 5292646
    Abstract: This invention provides a fusion molecule comprising a DNA sequence encoding a thioredoxin-like protein fused to the DNA sequence encoding a selected heterologous peptide or protein. The peptide or protein may be fused to the amino terminus of the thioredoxin-like molecule, the carboxyl terminus of the thioredoxin-like molecule, or within the thioredoxin-like molecule, for example at the active-site loop of said molecule. Expression of this fusion molecule under the control of a regulatory sequence capable of directing its expression in a desired host cell, produces high levels of stable and soluble fusion protein. The fusion protein, located in the bacterial cytoplasm, may be selectively released from the cell by osmotic shock or freeze/thaw procedures. It may be optionally cleaved to liberate the soluble, correctly folded heterologous protein from the thioredoxin-like portion.
    Type: Grant
    Filed: July 28, 1992
    Date of Patent: March 8, 1994
    Assignee: Genetics Institute, Inc.
    Inventors: John McCoy, Edward R. LaVallie
  • Patent number: 5290549
    Abstract: Methods are presented for improving the lipoprotein cholesterol profile of a mammal. Methods are also presented for reducing or removing atherosclerotic lesions from a mammal that has such lesions. The methods comprise administering to the mammal a therapeutic amount of an M-CSF protein in combination with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: October 16, 1992
    Date of Patent: March 1, 1994
    Assignee: Genetics Institute, Inc.-Legal Affairs
    Inventor: Marc B. Garnick
  • Patent number: 5278065
    Abstract: The invention described encompasses an isolated DNA sequence encoding all or a portion thereof of a cell surface receptor for murine and human erythropoietin (hereinafter EPO-R), along with the isolated polypeptide expressed by the DNA sequence (i.e., isolated EPO-R). The invention also encompasses host cells containing the above-described DNA sequence, preferably, host cells which express the polypeptide encoded by the DNA sequence (EPO-R) at a significantly higher level than that produced by normal red blood cell precursors. The invention further encompasses DNA sequences encoding secreted forms of the human EPO-R and polypeptides corresponding thereto. The EPO-receptor in all of the disclosed forms can be used as models for designing drugs or in pharmaceutical compositions for treating anemias.
    Type: Grant
    Filed: March 25, 1991
    Date of Patent: January 11, 1994
    Assignees: Genetics Institute, Inc., Whitehead Institute for Biomedical Research, The Children's Medical Center Corporation
    Inventors: Alan D'Andrea, Gordon G. Wong, Simon S. Jones
  • Patent number: 5270181
    Abstract: This invention provides a fusion molecule comprising a DNA sequence encoding a thioredoxin-like protein fused to the DNA sequence encoding a selected heterologous peptide or protein. The peptide or protein may be fused to the amino terminus of the thioredoxin-like molecule, the carboxyl terminus of the thioredoxin-like molecule, or within the thioredoxin-like molecule, for example at the active-site loop of said molecule. Expression of this fusion molecule under the control of a regulatory sequence capable of directing its expression in a desired host cell, produces high levels of stable and soluble fusion protein. The fusion protein, located in the bacterial cytoplasm, may be selectively released from the cell by osmotic shock or freeze/thaw procedures. It may be optionally cleaved to liberate the soluble, correctly folded heterologous protein from the thioredoxin-like portion.
    Type: Grant
    Filed: August 14, 1991
    Date of Patent: December 14, 1993
    Assignee: Genetics Institute, Inc.
    Inventors: John McCoy, Edward R. LaVallie
  • Patent number: 5268285
    Abstract: The present invention provides a process for increasing the rate of production of carbon dioxide, ethanol and other fermentation products such as citric acid, produced by yeast such as Saccharomyces cerevisiae during fermentation, and decreasing biomass production by regulating the rate of glycolysis indirectly through changing the energy balance of the cell, i.e., by reducing intracellular ATP levels. Modifications for so altering the glycolysis rate involve the use of either a regulated ATP hydrolysis within the cell or a regulated leakage of ATP from the cell.
    Type: Grant
    Filed: July 22, 1991
    Date of Patent: December 7, 1993
    Assignee: Genetics Institute, Inc.
    Inventors: David T. Rogers, Jack W. Szostak
  • Patent number: 5258298
    Abstract: Thrombolytic proteins are disclosed which have tissue plasminogen-type activity. The proteins are characterized by modification within the 94 amino acid N-terminus, and/or at Arg-275, and/or at one or more of the N-linked glycosylation sites. Methods for making these proteins are disclosed as are therapeutic compositions containing same.
    Type: Grant
    Filed: December 10, 1991
    Date of Patent: November 2, 1993
    Assignee: Genetics Institute, Inc.
    Inventors: Glenn R. Larsen, Tim J. Ahern
  • Patent number: 5250421
    Abstract: An improved method for producing Factor VIII:c-type proteins is disclosed which involves culturing mammalian cells which are capable of expressing the protein. In accordance with this invention the cells are cultured in a medium containing an effective amount of a substance comprising (a) von Willebrand Factor-type protein, (b) a phospholipid or phospholipid mixture, or a mixture of (a) and (b).
    Type: Grant
    Filed: January 17, 1992
    Date of Patent: October 5, 1993
    Assignee: Genetics Institute, Inc.
    Inventors: Randal J. Kaufman, S. Robert Adamson
  • Patent number: 5238820
    Abstract: A transformation vector containing a heterologous product gene and two or more different heterologous selectable amplifiable marker genes is described. Preferably, the marker genes form a polycistronic transcription unit. Also described is a method for obtaining high level expression of a desired protein by culturing eukaryotic cells containing the vectors of the invention.
    Type: Grant
    Filed: October 13, 1989
    Date of Patent: August 24, 1993
    Assignee: Genetics Institute, Inc.
    Inventor: Randal J. Kaufman
  • Patent number: 5215895
    Abstract: A novel mammalian cytokine, IL-11, and processes for producing it are disclosed. IL-11 may be used in pharmaceutical preparations for stimulating and/or enhancing cells involved in the immune response and cells involved in the proper functioning of the hematopoietic system.
    Type: Grant
    Filed: May 21, 1990
    Date of Patent: June 1, 1993
    Assignee: Genetics Institute, Inc.
    Inventors: Frances K. Bennett, Stephen R. Paul, Yu-Chung Yang
  • Patent number: 5212073
    Abstract: A novel human cytokine, JE factor, and processes for producing it are disclosed. JE may be used in pharmaceutical preparations for stimulating and/or enhancing immune responsiveness and in wound healing and related tissue repair.
    Type: Grant
    Filed: May 12, 1989
    Date of Patent: May 18, 1993
    Assignees: Genetics Institute, Inc., Dana Farber Cancer Inst.
    Inventors: Barrett Rollins, Charles Stiles, Gordon G. Wong
  • Patent number: 5198417
    Abstract: Disclosed herein is the treatment of patients suffering from AIDS-type disease with erythropoietin alone or together with a colony stimulating factor, and/or an anti-viral agent and/or IL-2.
    Type: Grant
    Filed: November 7, 1989
    Date of Patent: March 30, 1993
    Assignee: Genetics Institute, Inc.
    Inventor: Robert E. Donahue
  • Patent number: 5187076
    Abstract: Purified BMP-6 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.
    Type: Grant
    Filed: March 7, 1990
    Date of Patent: February 16, 1993
    Assignee: Genetics Institute, Inc.
    Inventors: John M. Wozney, Elizabeth A. Wang, Vicki A. Rosen, Anthony J. Celeste
  • Patent number: 5166058
    Abstract: Purified BMP-2 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
    Type: Grant
    Filed: July 11, 1989
    Date of Patent: November 24, 1992
    Assignee: Genetics Institute, Inc.
    Inventors: Elizabeth A. Wang, John M. Wozney, Vicki A. Rosen
  • Patent number: 5141905
    Abstract: Purified BMP-7 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartlage defects and in wound healing and related tissue repair.
    Type: Grant
    Filed: November 17, 1989
    Date of Patent: August 25, 1992
    Inventors: Vicki A. Rosen, Elizabeth A. Wang, John M. Wozney
  • Patent number: 5126323
    Abstract: Homogeneous K-FGF and a process for its production are provided. Also provided are pharmaceutical compositions for use in treating soft tissue injuries and musculo-skeletal disorders in mammals and methods of treatment. The purification of the bacterially produced K-FGF comprises reduction of a salt solution containing K-FGF to effect the precipitation of the product.
    Type: Grant
    Filed: November 16, 1989
    Date of Patent: June 30, 1992
    Assignee: Genetics Institute, Inc.
    Inventors: David T. Rogers, Neil M. Wolfman, Jasbir S. Seehra